嘉和生物(06998.HK)今日复牌后股价大涨87.88%,引发市场关注。根据公告显示,公司将以合并方式收购亿腾医药集团,预计合并完成后将为公司带来协同效应,增强商业化能力。
嘉和生物宣布将以发行18.2亿股新股作为代价收购亿腾医药,合并完成后,亿腾医药将成为嘉和生物的全资附属公司。公司指出,收购亿腾医药是因为其预期自身CDK4/6i肿瘤创新药物商业化在即,需要有强大的商业能力来把握市场机遇,而亿腾医药正拥有符合公司需求的实力。
公司表示,亿腾医药集团拥有领先的创新专利药物和具竞争力的原研产品,并具备完善的商业化平台、行业领先的销售营销网络以及先进制造平台。因此,建议合并预计将为双方带来互补协同效应,为合并后的经扩大集团的可持续发展奠定良好基础。届时嘉和生物亦将更名为"亿腾嘉和医药集团"。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.